Cargando…
Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer?
With a 5-year survival rate of fewer than 50%, epithelial ovarian carcinoma is the most fatal of the gynecologic cancers. Each year, an estimated 22,000 women are diagnosed with the condition, with 14,000 dying as a result, in the United States. Over the last decade, the advent of molecular and gene...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486999/ https://www.ncbi.nlm.nih.gov/pubmed/37685447 http://dx.doi.org/10.3390/healthcare11172413 |
_version_ | 1785103130735673344 |
---|---|
author | Macchia, Gabriella Titone, Francesca Restaino, Stefano Arcieri, Martina Pellecchia, Giulia Andreetta, Claudia Driul, Lorenza Vizzielli, Giuseppe Pezzulla, Donato |
author_facet | Macchia, Gabriella Titone, Francesca Restaino, Stefano Arcieri, Martina Pellecchia, Giulia Andreetta, Claudia Driul, Lorenza Vizzielli, Giuseppe Pezzulla, Donato |
author_sort | Macchia, Gabriella |
collection | PubMed |
description | With a 5-year survival rate of fewer than 50%, epithelial ovarian carcinoma is the most fatal of the gynecologic cancers. Each year, an estimated 22,000 women are diagnosed with the condition, with 14,000 dying as a result, in the United States. Over the last decade, the advent of molecular and genetic data has enhanced our understanding of the heterogeneity of ovarian cancer. More than 80% of women diagnosed with advanced illness have an initial full response to rigorous therapy at diagnosis, including surgery and platinum-based chemotherapy. Unfortunately, these responses are infrequently lasting, and the majority of women with ovarian cancer suffer recurrent disease, which is often incurable, despite the possibility of future response and months of survival. And what therapeutic weapons do we have to counter it? For many years, radiation therapy for ovarian tumors was disregarded as an effective treatment option due to its toxicity and lack of survival benefits. Chemotherapy is widely used following surgery, and it has nearly completely supplanted radiation therapy. Even with the use of more modern and efficient chemotherapy regimens, ovarian cancer failures still happen. After receiving first-line ovarian cancer chemotherapy, over 70% of patients show evidence of recurrence in the abdomen or pelvis. It is necessary to reinterpret the function of radiation therapy in light of recent technological developments, the sophistication of radiation procedures, and the molecular and biological understanding of various histological subtypes. This review article focuses on the literature on the use of radiation in ovarian tumors as well as its rationale and current indications. |
format | Online Article Text |
id | pubmed-10486999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104869992023-09-09 Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer? Macchia, Gabriella Titone, Francesca Restaino, Stefano Arcieri, Martina Pellecchia, Giulia Andreetta, Claudia Driul, Lorenza Vizzielli, Giuseppe Pezzulla, Donato Healthcare (Basel) Review With a 5-year survival rate of fewer than 50%, epithelial ovarian carcinoma is the most fatal of the gynecologic cancers. Each year, an estimated 22,000 women are diagnosed with the condition, with 14,000 dying as a result, in the United States. Over the last decade, the advent of molecular and genetic data has enhanced our understanding of the heterogeneity of ovarian cancer. More than 80% of women diagnosed with advanced illness have an initial full response to rigorous therapy at diagnosis, including surgery and platinum-based chemotherapy. Unfortunately, these responses are infrequently lasting, and the majority of women with ovarian cancer suffer recurrent disease, which is often incurable, despite the possibility of future response and months of survival. And what therapeutic weapons do we have to counter it? For many years, radiation therapy for ovarian tumors was disregarded as an effective treatment option due to its toxicity and lack of survival benefits. Chemotherapy is widely used following surgery, and it has nearly completely supplanted radiation therapy. Even with the use of more modern and efficient chemotherapy regimens, ovarian cancer failures still happen. After receiving first-line ovarian cancer chemotherapy, over 70% of patients show evidence of recurrence in the abdomen or pelvis. It is necessary to reinterpret the function of radiation therapy in light of recent technological developments, the sophistication of radiation procedures, and the molecular and biological understanding of various histological subtypes. This review article focuses on the literature on the use of radiation in ovarian tumors as well as its rationale and current indications. MDPI 2023-08-28 /pmc/articles/PMC10486999/ /pubmed/37685447 http://dx.doi.org/10.3390/healthcare11172413 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Macchia, Gabriella Titone, Francesca Restaino, Stefano Arcieri, Martina Pellecchia, Giulia Andreetta, Claudia Driul, Lorenza Vizzielli, Giuseppe Pezzulla, Donato Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer? |
title | Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer? |
title_full | Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer? |
title_fullStr | Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer? |
title_full_unstemmed | Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer? |
title_short | Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer? |
title_sort | is it time to reassess the role of radiotherapy treatment in ovarian cancer? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486999/ https://www.ncbi.nlm.nih.gov/pubmed/37685447 http://dx.doi.org/10.3390/healthcare11172413 |
work_keys_str_mv | AT macchiagabriella isittimetoreassesstheroleofradiotherapytreatmentinovariancancer AT titonefrancesca isittimetoreassesstheroleofradiotherapytreatmentinovariancancer AT restainostefano isittimetoreassesstheroleofradiotherapytreatmentinovariancancer AT arcierimartina isittimetoreassesstheroleofradiotherapytreatmentinovariancancer AT pellecchiagiulia isittimetoreassesstheroleofradiotherapytreatmentinovariancancer AT andreettaclaudia isittimetoreassesstheroleofradiotherapytreatmentinovariancancer AT driullorenza isittimetoreassesstheroleofradiotherapytreatmentinovariancancer AT vizzielligiuseppe isittimetoreassesstheroleofradiotherapytreatmentinovariancancer AT pezzulladonato isittimetoreassesstheroleofradiotherapytreatmentinovariancancer |